Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults
301 healthy adult volunteers were randomized to one of three treatment groups: inactivated hepatitis A vaccine alone; inactivated hepatitis A vaccine with immune globulin (Ig) concurrently; or Ig alone. The first two treatment groups received a second dose of hepatitis A vaccine at week 24. Anti-HAV...
Gespeichert in:
| Veröffentlicht in: | Vaccine 1999-03, Vol.17 (11), p.1468-1473 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1473 |
|---|---|
| container_issue | 11 |
| container_start_page | 1468 |
| container_title | Vaccine |
| container_volume | 17 |
| creator | Walter, Emmanuel B Hornick, Richard B Poland, Gregory A Richard Tucker Bland, Christine L Clements, Dennis A Rhamstine, Chloe C Jacobson, Robert M Brown, Leora Gress, Jacqueline O Harris, Katherine E Wiens, Brian L Nalin, David R |
| description | 301 healthy adult volunteers were randomized to one of three treatment groups: inactivated hepatitis A vaccine alone; inactivated hepatitis A vaccine with immune globulin (Ig) concurrently; or Ig alone. The first two treatment groups received a second dose of hepatitis A vaccine at week 24. Anti-HAV was measured 4, 8, 12, 24 and 28 weeks after the primary immunization. When comparing subjects receiving inactivated hepatitis A vaccine alone to those receiving vaccine and Ig, the seropositivity rates were not significantly different at 4, 8, 12 and 28 weeks, but at week 24 the seropositivity rate was lower in the group receiving both vaccine and Ig compared to the group receiving vaccine alone (92.0% compared to 97.0%). At weeks 8, 12 and 24 the geometric mean titers (GMTs) were significantly lower for subjects receiving both vaccine and Ig. The GMTs were not significantly different after the second dose of vaccine. At all time points, the lower serum antibody concentrations observed in subjects receiving both inactivated hepatitis A vaccine and Ig were nevertheless substantially higher than the cutoff for assay seropositivity and much higher than after Ig alone; these differences are therefore clinically insignificant. |
| doi_str_mv | 10.1016/S0264-410X(98)00370-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69677629</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X98003703</els_id><sourcerecordid>17211124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-e7602fdee75d040aecb7e1790c95467cbdef2adb561f698dec360b58cf1d29753</originalsourceid><addsrcrecordid>eNqFkUuLFDEUhYMoTs_oT1BqITIuSvOoJJWVDI0vGHChgruQurllR6pSbZJqmX9vZrpRd7PKJXzn3Ms5hDxj9DWjTL35Qrnq2o7R75emf0Wp0LQVD8iG9Vq0XLL-Idn8Rc7Iec4_KaVSMPOYnFUHI3UvNgS2S4Q1JYylcX4OMeSSXAlLbJaxCdFBCQdX0Dc73Nf_EnJz1RwcQIjY_A5l14R5Xuv8Y1qGdQqxiirrprK7qY7rVPIT8mh0U8anp_eCfHv_7uv2Y3v9-cOn7dV1Cx1npUWtKB89opaedtQhDBqZNhSM7JSGwePInR-kYqMyvUcQig6yh5F5brQUF-Tl0Xefll8r5mLnkAGnyUVc1myVUVorbu4FmeaMMd5VUB5BSEvOCUe7T2F26cYyam9rsHc12NuMrentXQ1WVN3z04J1mNH_pzrmXoEXJ8BlcNOYXISQ_3G6Ex3tK_b2iGGN7RAw2QwBI6APCaFYv4R7LvkDkkKmUQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17211124</pqid></control><display><type>article</type><title>Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Walter, Emmanuel B ; Hornick, Richard B ; Poland, Gregory A ; Richard Tucker ; Bland, Christine L ; Clements, Dennis A ; Rhamstine, Chloe C ; Jacobson, Robert M ; Brown, Leora ; Gress, Jacqueline O ; Harris, Katherine E ; Wiens, Brian L ; Nalin, David R</creator><creatorcontrib>Walter, Emmanuel B ; Hornick, Richard B ; Poland, Gregory A ; Richard Tucker ; Bland, Christine L ; Clements, Dennis A ; Rhamstine, Chloe C ; Jacobson, Robert M ; Brown, Leora ; Gress, Jacqueline O ; Harris, Katherine E ; Wiens, Brian L ; Nalin, David R</creatorcontrib><description>301 healthy adult volunteers were randomized to one of three treatment groups: inactivated hepatitis A vaccine alone; inactivated hepatitis A vaccine with immune globulin (Ig) concurrently; or Ig alone. The first two treatment groups received a second dose of hepatitis A vaccine at week 24. Anti-HAV was measured 4, 8, 12, 24 and 28 weeks after the primary immunization. When comparing subjects receiving inactivated hepatitis A vaccine alone to those receiving vaccine and Ig, the seropositivity rates were not significantly different at 4, 8, 12 and 28 weeks, but at week 24 the seropositivity rate was lower in the group receiving both vaccine and Ig compared to the group receiving vaccine alone (92.0% compared to 97.0%). At weeks 8, 12 and 24 the geometric mean titers (GMTs) were significantly lower for subjects receiving both vaccine and Ig. The GMTs were not significantly different after the second dose of vaccine. At all time points, the lower serum antibody concentrations observed in subjects receiving both inactivated hepatitis A vaccine and Ig were nevertheless substantially higher than the cutoff for assay seropositivity and much higher than after Ig alone; these differences are therefore clinically insignificant.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(98)00370-3</identifier><identifier>PMID: 10195783</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Biological and medical sciences ; Drug Administration Schedule ; Drug Therapy, Combination ; Epidemiology. Vaccinations ; General aspects ; Hepatitis A Antibodies ; Hepatitis A vaccine ; Hepatitis A Vaccines ; Hepatitis A virus ; Hepatitis Antibodies - biosynthesis ; Humans ; Immune globulin ; Immunoglobulins - administration & dosage ; Immunoglobulins - immunology ; Infectious diseases ; Medical sciences ; Vaccines, Attenuated - administration & dosage ; Vaccines, Attenuated - immunology ; Viral Hepatitis Vaccines - administration & dosage ; Viral Hepatitis Vaccines - immunology</subject><ispartof>Vaccine, 1999-03, Vol.17 (11), p.1468-1473</ispartof><rights>1999</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-e7602fdee75d040aecb7e1790c95467cbdef2adb561f698dec360b58cf1d29753</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X98003703$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1743408$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10195783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walter, Emmanuel B</creatorcontrib><creatorcontrib>Hornick, Richard B</creatorcontrib><creatorcontrib>Poland, Gregory A</creatorcontrib><creatorcontrib>Richard Tucker</creatorcontrib><creatorcontrib>Bland, Christine L</creatorcontrib><creatorcontrib>Clements, Dennis A</creatorcontrib><creatorcontrib>Rhamstine, Chloe C</creatorcontrib><creatorcontrib>Jacobson, Robert M</creatorcontrib><creatorcontrib>Brown, Leora</creatorcontrib><creatorcontrib>Gress, Jacqueline O</creatorcontrib><creatorcontrib>Harris, Katherine E</creatorcontrib><creatorcontrib>Wiens, Brian L</creatorcontrib><creatorcontrib>Nalin, David R</creatorcontrib><title>Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>301 healthy adult volunteers were randomized to one of three treatment groups: inactivated hepatitis A vaccine alone; inactivated hepatitis A vaccine with immune globulin (Ig) concurrently; or Ig alone. The first two treatment groups received a second dose of hepatitis A vaccine at week 24. Anti-HAV was measured 4, 8, 12, 24 and 28 weeks after the primary immunization. When comparing subjects receiving inactivated hepatitis A vaccine alone to those receiving vaccine and Ig, the seropositivity rates were not significantly different at 4, 8, 12 and 28 weeks, but at week 24 the seropositivity rate was lower in the group receiving both vaccine and Ig compared to the group receiving vaccine alone (92.0% compared to 97.0%). At weeks 8, 12 and 24 the geometric mean titers (GMTs) were significantly lower for subjects receiving both vaccine and Ig. The GMTs were not significantly different after the second dose of vaccine. At all time points, the lower serum antibody concentrations observed in subjects receiving both inactivated hepatitis A vaccine and Ig were nevertheless substantially higher than the cutoff for assay seropositivity and much higher than after Ig alone; these differences are therefore clinically insignificant.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Epidemiology. Vaccinations</subject><subject>General aspects</subject><subject>Hepatitis A Antibodies</subject><subject>Hepatitis A vaccine</subject><subject>Hepatitis A Vaccines</subject><subject>Hepatitis A virus</subject><subject>Hepatitis Antibodies - biosynthesis</subject><subject>Humans</subject><subject>Immune globulin</subject><subject>Immunoglobulins - administration & dosage</subject><subject>Immunoglobulins - immunology</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Vaccines, Attenuated - administration & dosage</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Viral Hepatitis Vaccines - administration & dosage</subject><subject>Viral Hepatitis Vaccines - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUuLFDEUhYMoTs_oT1BqITIuSvOoJJWVDI0vGHChgruQurllR6pSbZJqmX9vZrpRd7PKJXzn3Ms5hDxj9DWjTL35Qrnq2o7R75emf0Wp0LQVD8iG9Vq0XLL-Idn8Rc7Iec4_KaVSMPOYnFUHI3UvNgS2S4Q1JYylcX4OMeSSXAlLbJaxCdFBCQdX0Dc73Nf_EnJz1RwcQIjY_A5l14R5Xuv8Y1qGdQqxiirrprK7qY7rVPIT8mh0U8anp_eCfHv_7uv2Y3v9-cOn7dV1Cx1npUWtKB89opaedtQhDBqZNhSM7JSGwePInR-kYqMyvUcQig6yh5F5brQUF-Tl0Xefll8r5mLnkAGnyUVc1myVUVorbu4FmeaMMd5VUB5BSEvOCUe7T2F26cYyam9rsHc12NuMrentXQ1WVN3z04J1mNH_pzrmXoEXJ8BlcNOYXISQ_3G6Ex3tK_b2iGGN7RAw2QwBI6APCaFYv4R7LvkDkkKmUQ</recordid><startdate>19990317</startdate><enddate>19990317</enddate><creator>Walter, Emmanuel B</creator><creator>Hornick, Richard B</creator><creator>Poland, Gregory A</creator><creator>Richard Tucker</creator><creator>Bland, Christine L</creator><creator>Clements, Dennis A</creator><creator>Rhamstine, Chloe C</creator><creator>Jacobson, Robert M</creator><creator>Brown, Leora</creator><creator>Gress, Jacqueline O</creator><creator>Harris, Katherine E</creator><creator>Wiens, Brian L</creator><creator>Nalin, David R</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19990317</creationdate><title>Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults</title><author>Walter, Emmanuel B ; Hornick, Richard B ; Poland, Gregory A ; Richard Tucker ; Bland, Christine L ; Clements, Dennis A ; Rhamstine, Chloe C ; Jacobson, Robert M ; Brown, Leora ; Gress, Jacqueline O ; Harris, Katherine E ; Wiens, Brian L ; Nalin, David R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-e7602fdee75d040aecb7e1790c95467cbdef2adb561f698dec360b58cf1d29753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Epidemiology. Vaccinations</topic><topic>General aspects</topic><topic>Hepatitis A Antibodies</topic><topic>Hepatitis A vaccine</topic><topic>Hepatitis A Vaccines</topic><topic>Hepatitis A virus</topic><topic>Hepatitis Antibodies - biosynthesis</topic><topic>Humans</topic><topic>Immune globulin</topic><topic>Immunoglobulins - administration & dosage</topic><topic>Immunoglobulins - immunology</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Vaccines, Attenuated - administration & dosage</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Viral Hepatitis Vaccines - administration & dosage</topic><topic>Viral Hepatitis Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walter, Emmanuel B</creatorcontrib><creatorcontrib>Hornick, Richard B</creatorcontrib><creatorcontrib>Poland, Gregory A</creatorcontrib><creatorcontrib>Richard Tucker</creatorcontrib><creatorcontrib>Bland, Christine L</creatorcontrib><creatorcontrib>Clements, Dennis A</creatorcontrib><creatorcontrib>Rhamstine, Chloe C</creatorcontrib><creatorcontrib>Jacobson, Robert M</creatorcontrib><creatorcontrib>Brown, Leora</creatorcontrib><creatorcontrib>Gress, Jacqueline O</creatorcontrib><creatorcontrib>Harris, Katherine E</creatorcontrib><creatorcontrib>Wiens, Brian L</creatorcontrib><creatorcontrib>Nalin, David R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walter, Emmanuel B</au><au>Hornick, Richard B</au><au>Poland, Gregory A</au><au>Richard Tucker</au><au>Bland, Christine L</au><au>Clements, Dennis A</au><au>Rhamstine, Chloe C</au><au>Jacobson, Robert M</au><au>Brown, Leora</au><au>Gress, Jacqueline O</au><au>Harris, Katherine E</au><au>Wiens, Brian L</au><au>Nalin, David R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>1999-03-17</date><risdate>1999</risdate><volume>17</volume><issue>11</issue><spage>1468</spage><epage>1473</epage><pages>1468-1473</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>301 healthy adult volunteers were randomized to one of three treatment groups: inactivated hepatitis A vaccine alone; inactivated hepatitis A vaccine with immune globulin (Ig) concurrently; or Ig alone. The first two treatment groups received a second dose of hepatitis A vaccine at week 24. Anti-HAV was measured 4, 8, 12, 24 and 28 weeks after the primary immunization. When comparing subjects receiving inactivated hepatitis A vaccine alone to those receiving vaccine and Ig, the seropositivity rates were not significantly different at 4, 8, 12 and 28 weeks, but at week 24 the seropositivity rate was lower in the group receiving both vaccine and Ig compared to the group receiving vaccine alone (92.0% compared to 97.0%). At weeks 8, 12 and 24 the geometric mean titers (GMTs) were significantly lower for subjects receiving both vaccine and Ig. The GMTs were not significantly different after the second dose of vaccine. At all time points, the lower serum antibody concentrations observed in subjects receiving both inactivated hepatitis A vaccine and Ig were nevertheless substantially higher than the cutoff for assay seropositivity and much higher than after Ig alone; these differences are therefore clinically insignificant.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10195783</pmid><doi>10.1016/S0264-410X(98)00370-3</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 1999-03, Vol.17 (11), p.1468-1473 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69677629 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Biological and medical sciences Drug Administration Schedule Drug Therapy, Combination Epidemiology. Vaccinations General aspects Hepatitis A Antibodies Hepatitis A vaccine Hepatitis A Vaccines Hepatitis A virus Hepatitis Antibodies - biosynthesis Humans Immune globulin Immunoglobulins - administration & dosage Immunoglobulins - immunology Infectious diseases Medical sciences Vaccines, Attenuated - administration & dosage Vaccines, Attenuated - immunology Viral Hepatitis Vaccines - administration & dosage Viral Hepatitis Vaccines - immunology |
| title | Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T18%3A06%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Concurrent%20administration%20of%20inactivated%20hepatitis%20A%20vaccine%20with%20immune%20globulin%20in%20healthy%20adults&rft.jtitle=Vaccine&rft.au=Walter,%20Emmanuel%20B&rft.date=1999-03-17&rft.volume=17&rft.issue=11&rft.spage=1468&rft.epage=1473&rft.pages=1468-1473&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(98)00370-3&rft_dat=%3Cproquest_cross%3E17211124%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17211124&rft_id=info:pmid/10195783&rft_els_id=S0264410X98003703&rfr_iscdi=true |